News for ABL Bio Inc. (298380.KQ)

Published at

Jun 24, 2024 9:00 PM

by globenewswire.com

neutral

neutral

Global Parkinson’s Disease Treatment Market Size To Worth USD 9.14 Billion By 2033 | CAGR Of 6.41%

The Global Parkinson's Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinson's Disease Treatment Market Size is...

NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA GNE.PA GEC.L GEC.DE GE.SW GE.SN GE.MX GE ABTCL.SN ABT.SN ABT 298380.KQ 0K9E.L

Read more →
Published at

Sep 13, 2023 9:00 AM

by prnewswire.com

positive

positive

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

/PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of...

298380.KQ

Read more →
Published at

Apr 3, 2023 5:30 PM

by prnewswire.com

mixed

mixed

Bispecific antibodies for cancer market size to grow by USD 400.72 million between 2022 and 2027; Growth driven by the increasing prevalence of cancer - Technavio

/PRNewswire/ -- The bispecific antibodies for cancer market size is forecasted to increase by USD 400.72 million from 2022 to 2027, at a CAGR of 8.82%,...

YMAB TGTX REGN34.SA REGN.MX REGN FSTX 0VGI.L 0R2M.L PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE MRUS MREO MPH.L CHGCY CHGCF APVO ALPMY ALPMF AFMD 4519.T 4503N.MX 0HL9.L 0A9G.L XNCR AMGN.MX AMGN.BA AMGN AMG.DE 9926.HK 298380.KQ

Read more →
Published at

Sep 29, 2022 12:30 AM

by prnewswire.com

mixed

mixed

Bispecific Antibodies for Cancer Market Size to Grow by USD 396.56 million, Emerging Bispecific Antibody Generation Platforms to be Key Trend - Technavio

/PRNewswire/ -- In the bispecific antibodies for cancer market, emerging bispecific antibody generation platforms will be a key trend during the forecast...

CHGCY CHGCF APVO AFMD 9926.HK 4519.T 0HL9.L YMAB XNCR TGTX REGN34.SA REGN.MX REGN PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE MRUS MREO MPH.L FSTX AMGN.MX AMGN.BA AMGN AMG.DE ALPMY ALPMF 4503N.MX 298380.KQ 0VGI.L 0R2M.L 0A9G.L

Read more →
Published at

Mar 9, 2022 8:30 AM

by prnewswire.com

mixed

mixed

Bispecific Antibodies for Cancer Market will Register 6.44% YOY Growth in 2022 | 39% Growth to Originate from North America| 17,000+ Technavio Reports

/PRNewswire/ -- According to the market analysis report "Bispecific Antibodies for Cancer Market by Type and Geography - Forecast and Analysis 2022-2026", the...

YMAB XNCR TGTX REGN34.SA REGN.MX REGN PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE MRUS MREO MPH.L CHGCY CHGCF APVO AFMD 9926.HK 4519.T 0VGI.L 0R2M.L 0HL9.L 0A9G.L FSTX AMGN.MX AMGN.BA AMGN AMG.DE ALPMY ALPMF 4503N.MX 298380.KQ

Read more →
Published at

Jan 12, 2022 12:53 AM

by prnewswire.com

positive

positive

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

/PRNewswire/ -- ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative...

298380.KQ

Read more →
Published at

Nov 9, 2021 2:05 PM

by prnewswire.com

mixed

mixed

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC

/PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel...

YI IMAB 298380.KQ

Read more →
Published at

Oct 8, 2021 6:08 PM

by marketscreener.com

neutral

neutral

Compass Therapeutics : CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and

CTX-009 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric... | October 8, 2021

CMPX 298380.KQ

Read more →
Published at

Oct 8, 2021 6:07 PM

by thestreet.com

neutral

neutral

CTX-009 (ABL001/ES104) Clinical Data Presented Today At The New Drugs On The Horizon Plenary Session Of The 2021 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Compass Therapeutics, Inc. (OTC:CMPX) and ABL Bio (KOSDAQ: 298380) presented today clinical trial data for CTX-009 (ABL001/ES104), a dual anti-angiogenic

CMPX 298380.KQ

Read more →
Published at

Oct 1, 2021 1:03 PM

by marketscreener.com

mixed

mixed

Compass Therapeutics : and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Compass Therapeutics, Inc. , a clinical-stage, oncology focused biotechnology company developing proprietary immuno-modulatory and anti-angiogenic antibody therapeutics, and ABL Bio, Inc. , a... | October 1, 2021

038880.KQ CMPX 298380.KQ

Read more →